Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Back to the List
Type(s) of Cancer
Multiple Myeloma
Study Phase
Phase 3
Study Completion Date
2008
NCT00644228Uploaded 08-21-2019
Access via NCI by Request
PDS UID: nci-data-360
N/A
Provider Information
Provider Data DescriptionThe dataset NCT00644228-D2-Dataset.csv will allow users to reproduce safety analyses included in the aforementioned publication, which compared toxicity between bortezomib, lenalidomide and low dose dexamethasone versus lenalidomide and low dose dexamethasone induction therapy for the treatment of patients with newly diagnosed multiple myeloma in the SWOG phase III trial, S0777.
SponsorNational Cancer Institute
Data ProviderNational Cancer Institute
Clinical Trials.gov Information
Brief SummaryN/A
ConditionsN/A
Intervention TypeDrug
Drug(s)N/A
Total EnrolledN/A
RandomizationN/A
Blinding MethodN/A
Arms InterventionN/A
Secondary IDN/A
PubMed (PMID)N/A
Collaborator(s)N/A
Region(s)N/A
Age RangeN/A
Files: NCT00644228-D2
Data DictionaryNCT00644228-D2-Data-Dictionary.pdf
DATANCT00644228-D2-Dataset.csv
OTHERREADME.pdf
Files: NCT00644228-D1
Data DictionaryNCT00644228-D1-Data-Dictionary.pdf
DATANCT00644228-D1-Dataset.csv
OTHERREADME.pdf
© 2023 Project Data Sphere
All rights reserved
Privacy PolicyTerms of Use